Impact of organ-on-a-chip technology on pharmaceutical R&D costs

Nora Franzen; Wim H. van Harten; Valesca P. Retèl; Peter Loskill; Janny van den Eijnden-van Raaij; Maarten IJzerman

doi:10.1016/j.drudis.2019.06.003

Impact of organ-on-a-chip technology on pharmaceutical R&D costs

Nora Franzen, Wim H. van Harten, Valesca P. Retèl, Peter Loskill, Janny van den Eijnden-van Raaij, Maarten IJzerman^*

^*Corresponding author for this work

Research output: Contribution to journal › Short survey › Academic › peer-review

110 Citations (Scopus)

101 Downloads (Pure)

Abstract

Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.

Original language	English
Pages (from-to)	1720-1724
Number of pages	5
Journal	Drug Discovery Today
Volume	24
Issue number	9
DOIs	https://doi.org/10.1016/j.drudis.2019.06.003
Publication status	Published - Sept 2019

Bibliographical note

Funding Information:
We are grateful to the 17 experts for their willingness and time to give interviews for the impact study. The authors would like to thank Massimo Mastrangeli (TU Delft, The Netherlands) and Sylvie Millet (CEA, Grenoble, France) for their support in defining the experts for the interviews; and Adele Tufford for her help with the review of the manuscript. Finally, we would like to express our sincere gratitude for the support of the ORCHID consortium to this research. This project has received funding from the EU’s Horizon 2020 research and innovation program under grant agreement no. 766884 .

Funding Information:
We are grateful to the 17 experts for their willingness and time to give interviews for the impact study. The authors would like to thank Massimo Mastrangeli (TU Delft, The Netherlands) and Sylvie Millet (CEA, Grenoble, France) for their support in defining the experts for the interviews; and Adele Tufford for her help with the review of the manuscript. Finally, we would like to express our sincere gratitude for the support of the ORCHID consortium to this research. This project has received funding from the EU's Horizon 2020 research and innovation program under grant agreement no. 766884.

Publisher Copyright:
© 2019 The Authors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.drudis.2019.06.003Licence: CC BY-NC-ND

Impact of organ-on-a-chip technology on pharmaceutical R&D costsFinal published version, 504 KBLicence: CC BY-NC-ND

Cite this

@article{4e9ee511cb73487e8c98df2f00e301e4,

title = "Impact of organ-on-a-chip technology on pharmaceutical R&D costs",

abstract = "Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.",

author = "Nora Franzen and {van Harten}, {Wim H.} and Ret{\`e}l, {Valesca P.} and Peter Loskill and {van den Eijnden-van Raaij}, Janny and Maarten IJzerman",

note = "Funding Information: We are grateful to the 17 experts for their willingness and time to give interviews for the impact study. The authors would like to thank Massimo Mastrangeli (TU Delft, The Netherlands) and Sylvie Millet (CEA, Grenoble, France) for their support in defining the experts for the interviews; and Adele Tufford for her help with the review of the manuscript. Finally, we would like to express our sincere gratitude for the support of the ORCHID consortium to this research. This project has received funding from the EU{\textquoteright}s Horizon 2020 research and innovation program under grant agreement no. 766884 . Funding Information: We are grateful to the 17 experts for their willingness and time to give interviews for the impact study. The authors would like to thank Massimo Mastrangeli (TU Delft, The Netherlands) and Sylvie Millet (CEA, Grenoble, France) for their support in defining the experts for the interviews; and Adele Tufford for her help with the review of the manuscript. Finally, we would like to express our sincere gratitude for the support of the ORCHID consortium to this research. This project has received funding from the EU's Horizon 2020 research and innovation program under grant agreement no. 766884. Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2019",

month = sep,

doi = "10.1016/j.drudis.2019.06.003",

language = "English",

volume = "24",

pages = "1720--1724",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd.",

number = "9",

}

TY - JOUR

T1 - Impact of organ-on-a-chip technology on pharmaceutical R&D costs

AU - Franzen, Nora

AU - van Harten, Wim H.

AU - Retèl, Valesca P.

AU - Loskill, Peter

AU - van den Eijnden-van Raaij, Janny

AU - IJzerman, Maarten

N1 - Funding Information: We are grateful to the 17 experts for their willingness and time to give interviews for the impact study. The authors would like to thank Massimo Mastrangeli (TU Delft, The Netherlands) and Sylvie Millet (CEA, Grenoble, France) for their support in defining the experts for the interviews; and Adele Tufford for her help with the review of the manuscript. Finally, we would like to express our sincere gratitude for the support of the ORCHID consortium to this research. This project has received funding from the EU’s Horizon 2020 research and innovation program under grant agreement no. 766884 . Funding Information: We are grateful to the 17 experts for their willingness and time to give interviews for the impact study. The authors would like to thank Massimo Mastrangeli (TU Delft, The Netherlands) and Sylvie Millet (CEA, Grenoble, France) for their support in defining the experts for the interviews; and Adele Tufford for her help with the review of the manuscript. Finally, we would like to express our sincere gratitude for the support of the ORCHID consortium to this research. This project has received funding from the EU's Horizon 2020 research and innovation program under grant agreement no. 766884. Publisher Copyright: © 2019 The Authors

PY - 2019/9

Y1 - 2019/9

N2 - Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.

AB - Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.

UR - http://www.scopus.com/inward/record.url?scp=85068251287&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2019.06.003

DO - 10.1016/j.drudis.2019.06.003

M3 - Short survey

C2 - 31185290

AN - SCOPUS:85068251287

SN - 1359-6446

VL - 24

SP - 1720

EP - 1724

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 9

ER -

Impact of organ-on-a-chip technology on pharmaceutical R&D costs

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this